• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Mylan

Mylan

Mylan NV MYL 2 Star

Last Price$61.63Day Change (%)-0.40%
Open Price$61.86Day Change ($)-0.25
Day Range61.29–62.4552-Week Range44.74–65.63

As of Fri 3/27/2015 5:00:00 PM | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  5. Research
  1. Mylan Launches First and Only Available Intermediate Dosage Strengths of Fentanyl Transdermal System 37.5, 62.5 and 87.5 mcg/hr

    Mylan Launches First and Only Available Intermediate Dosage Strengths of Fentanyl Transdermal System 37.5, 62.5 and 87.5 mcg/hr

  2. Mylan Launches Generic Subutex® Sublingual Tablets

    Mylan Launches Generic Subutex® Sublingual Tablets

  3. Mylan Completes Acquisition Of Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business

    Mylan Completes Acquisition Of Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business

  4. Rate Hikes? Not in 2015

    Watson Pharmaceuticals WPI scored big Tuesday when the Food and Drug Administration approved the firm's generic fentanyl patch. We may modestly increase our fair value estimate for Watson and will maintain our fair value estimate for competitor Mylan Laboratories MYL . The pain patch is one of the ...

  5. Berkshire Hathaway, Qualcomm, Mylan in focus

    Berkshire Hathaway, Qualcomm, Mylan in focus

  6. Mylan Files Annual Report on Form 10-K for Year Ended Dec. 31, 2014

    Mylan Files Annual Report on Form 10-K for Year Ended Dec. 31, 2014

  7. UPDATE: Berkshire Hathaway, Qualcomm, Mylan in focus

    UPDATE: Berkshire Hathaway, Qualcomm, Mylan in focus

  8. Mylan fourth-quarter earnings in-line with Street

    Mylan fourth-quarter earnings in-line with Street

  9. What Migration Can (and Can’t) Do for a Country’s GDP

    Mylan Laboratories MYL reported impressive second-quarter results Wednesday. However, most of the improvement was temporary and will not affect our fair value estimate. The quarter was only slightly better than we expected after excluding a one-time litigation payment and proceeds from a product ...

  10. Actavis' Wide-Moat Transformation Offers Shareholder Rewards

    Product durability, diversification, and cost synergies support strong earnings growth for this undervalued wide-moat firm.

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.